Compare Citius Pharmaceuticals Inc (CTXR) vs MKS Instruments (MKSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MKS Instruments — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while MKS Instruments trades at $264.5 (market cap $17.61B). The key difference: MKS Instruments is far larger — about 1293× Citius Pharmaceuticals Inc's market cap, and MKS Instruments pays a 0.38% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and MKS Instruments for 7 Days on average.
| CTXR | MKSI | |
|---|---|---|
Market Cap | $13.62M | $17.61B |
Volume | 132,438 | 1,275,355 |
Sector | Health | Technology |
52-Week High | $1.82 | $444.80 |
52-Week Low | $0.48 | $121.26 |
Typical Hold Time | 17 Days | 7 Days |
Enterprise Value | $3.79M | $21.18B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →
